Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

56.25 +3.55 (+6.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.